Respiratory failure attributable to moxidectin intoxication in a dog.

A 5-month-old 22-kg (48.4-lb) sexually intact male Collie was examined after ingesting a moxidectin-containing deworming medication. The dog was comatose and had respiratory arrest after progressively worsening lethargy, ataxia, and seizures. Exposure was confirmed by isolation of moxidectin from a biopsy specimen of adipose tissue, using liquid chromatography-mass spectroscopy methods. Treatment included use of intermittent positive-pressure ventilation, activated charcoal and cathartic administered enterally, nutrients administered via nasogastric tube, and intensive supportive care. The dog was weaned from a ventilator on day 6 after ingestion and was discharged on day 10. The dog was considered clinically normal during examination 24 days after ingestion. On the basis of the dog reported here and toxicologic data provided by the manufacturer of the deworming product, some Collies may have increased susceptibility to products containing high doses of moxidectin.

Pemoline toxicosis in a dog.

A 3-year-old German Short-haired Pointer was examined because of extreme agitation, hyperactivity, and vomiting that began within 24 hours after ingestion of approximately 750 mg of pemoline, a CNS stimulant. On physical examination, the dog was agitated, tachycardic, hyper-responsive, pyrectic, disoriented, and had mydriasis. These signs were consistent with excessive stimulation of the CNS and sympathomimetic effects resulting from pemoline toxicosis. Serial blood and urine samples were obtained, and toxicologic analyses were performed. Extrapolation of the plasma pemoline concentration 32 hours after ingestion provided an estimated peak plasma concentration of 368 micrograms/ml, dramatically higher than a therapeutic concentration of 1.7 to 7.0 micrograms/ml reported for children. Several sedatives were administered intravenously to alleviate clinical signs and to allow administration of activated charcoal (PO) and fluids (IV). Clinical signs resolved approximately 72 hours after ingestion of pemoline.

Studies of interactions of porphyrins with transfer RNA by high-resolution NMR.

The interactions of tetra-4N-methylpyridyl porphyrin and its zinc(II), copper(II) and manganese(III) complexes with brewer's yeast type V phenylalanine specific tRNA have been evaluated by high-resolution NMR. Differences in chemical shifts have been noted for three proton resonances in response to the presence of small quantities of the free base and the zinc and copper complexes. The protons giving rise to these signals are located on bases T54 and psi 55, both of which are involved in the primary intraloop and interloop hydrogen bonds that hold the D and T psi C loops together in the tertiary structure. In addition, broadening of specific resonances due to hydrogen bonding protons in the D stem at low ratios of porphyrin to tRNA indicates that the association of porphyrins increases the rate of imino proton exchange. The titration of the tRNA with the manganese(III) complex did not reveal shifts or specific broadening comparable to the other porphyrins at low ratios. The changes induced in the NMR spectrum of tRNA by porphyrins define their site of interaction with the polynucleotide. This site, at the outside of the elbow-bend in the tRNA 'L', is different from the locus of binding in tRNA for other classical DNA intercalators. Furthermore, a new mode of binding may be involved that is neither intercalative nor simply electrostatic.

Calcium and magnesium binding by parvalbumin. A proton magnetic resonance spectral study.

Proton magnetic resonance spectroscopy has been used to monitor the kinetics and nature of the conformational transitions induced by binding of calcium and magnesium to carp parvalbumin. Rate constants have been determined for the exchange between the cation dependent conformational states of the protein in solution. These data enable a description of the kinetics and mechanism controlling the calcium flux in vivo during contraction.